Promazine: Difference between revisions
m (Protected "Promazine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
Kiran Singh (talk | contribs) No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| IUPAC_name = N,N-dimethyl-3-(10H-phenothiazin-10-yl) propan-1-amine | | verifiedrevid = 464215585 | ||
| image = Promazine | | IUPAC_name = N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine | ||
| image =Promazine.png | |||
| width = 160 | | width = 160 | ||
| image2 =Promazine3d.png | |||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|CONS|promazine}} | |||
| MedlinePlus = a600010 | |||
| pregnancy_category = | |||
| legal_status = | |||
| routes_of_administration = | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = | |||
| protein_bound = 94% | |||
| metabolism = | |||
| elimination_half-life = | |||
| excretion = | |||
<!--Identifiers--> | |||
| CASNo_Ref = {{cascite|correct|CAS}} | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 58-40-2 | | CAS_number = 58-40-2 | ||
| ATC_prefix = N05 | | ATC_prefix = N05 | ||
| ATC_suffix = AA03 | | ATC_suffix = AA03 | ||
| ATC_supplemental = | | ATC_supplemental = | ||
| PubChem = 4926 | | PubChem = 4926 | ||
| DrugBank = | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| C=17 | H=20 | N=2 | S=1 | | DrugBank = DB00420 | ||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 4757 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = O9M39HTM5W | |||
| ChEBI_Ref = {{ebicite|correct|EBI}} | |||
| ChEBI = 8459 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 564 | |||
<!--Chemical data--> | |||
| C=17 | H=20 | N=2 | S=1 | |||
| molecular_weight = 284.42 g/mol | | molecular_weight = 284.42 g/mol | ||
| | | smiles = CN(C)CCCN1c2ccccc2Sc3c1cccc3 | ||
| | | InChI = 1/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3 | ||
| | | InChIKey = ZGUGWUXLJSTTMA-UHFFFAOYAX | ||
| | | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | ||
| | | StdInChI = 1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3 | ||
| | | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | ||
| StdInChIKey = ZGUGWUXLJSTTMA-UHFFFAOYSA-N | |||
| | |||
| | |||
}} | }} | ||
__Notoc__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Promazine''' ('''Sparine''') is a medication that belongs to the [[phenothiazine]] class of [[antipsychotics]]. An older medication used to treat [[schizophrenia]], it is still prescribed, alongside newer agents such as [[olanzapine]] and [[quetiapine]]. It has predominantly [[anticholinergic]] side effects, though [[extrapyramidal symptoms|extrapyramidal]] side effects are not uncommon either. | |||
'''Promazine''' ( | Promazine is not approved for human use in the United States. It is available in the US for veterinary use under the names Promazine and Tranquazine. | ||
==See also== | |||
*[[Chlorpromazine]] | |||
*[[Triflupromazine]] | |||
*[[Prochlorperazine]] | |||
*[[Trifluoperazine]] | |||
*[[Fluphenazine]] | |||
*[[Thioridazine]] | |||
*[[Mesoridazine]] | |||
{{Antipsychotics}} | {{Antipsychotics}} | ||
[[Category:Drug]] | |||
[[Category:Phenothiazines]] | [[Category:Phenothiazines]] | ||
Latest revision as of 15:09, 9 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a600010 |
ATC code | |
Pharmacokinetic data | |
Protein binding | 94% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C17H20N2S |
Molar mass | 284.42 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Promazine |
Articles |
---|
Most recent articles on Promazine |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Promazine at Clinical Trials.gov Clinical Trials on Promazine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Promazine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Promazine Discussion groups on Promazine Directions to Hospitals Treating Promazine Risk calculators and risk factors for Promazine
|
Healthcare Provider Resources |
Causes & Risk Factors for Promazine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Promazine (Sparine) is a medication that belongs to the phenothiazine class of antipsychotics. An older medication used to treat schizophrenia, it is still prescribed, alongside newer agents such as olanzapine and quetiapine. It has predominantly anticholinergic side effects, though extrapyramidal side effects are not uncommon either.
Promazine is not approved for human use in the United States. It is available in the US for veterinary use under the names Promazine and Tranquazine.